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Lun Jiang, Jing-Tao Wu* and Xin PengAbstract
Choriocarcinoma usually arises in the uterus and gonads. Primary choriocarcinoma (PCC) in an extragenital organ is
rare. When it occurs in the gastrointestinal tract, the stomach is the most common site. Only 12 cases of PCC of the
colon have been reported in the world literature. Most cases were associated with adenocarcinoma. We report the
case of a 36-year-old man with PCC of the colon and review the clinical characteristics of previously documented
cases.
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Choriocarcinoma is a highly malignant tumor of tropho-
blastic cells that most often arises in the female genital
tract. It is considered to be pertinent to molar preg-
nancy, normal or ectopic pregnancy and abortion. When
it occurs in male patients, the testis is the most common
site. Choriocarcinoma of extragenital origin is found in
the retroperitoneum or the mediastinum, or intracalvar-
ium. Primary choriocarcinoma (PCC) originating in the
colon is extremely rare and the prognosis is usually
poor.Case presentation
A 36-year-old male patient visited the local hospital for
the chief complaint of discomfort of the upper abdomen.
An appendectomy was performed under the clinical
diagnosis of acute appendicitis. During the operation, a
tumor was observed in the colon. The operation was
aborted because of an inability to remove the tumor.
Two days later, a computed tomographic (CT) scan of
the abdomen revealed the mass arising from the ascend-
ing colon. The regional enlarged lymph nodes and me-
tastases in the liver were noted (Figure 1).
The patient was transferred to our hospital for treat-
ment. Tumor markers, including carcinoembryonic anti-
gen, cancer antigen 19–9 (CA 19–9) and CA 125, were* Correspondence: wujingtaodoctor@126.com
Department of Medical Imaging, Su Bei People’s Hospital of JiangSu
Province, Medical School of Yangzhou University, No. 98 NanTong West
Road, Yangzhou, Jiangsu Province 225001, China
© 2013 Jiang et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orin the normal range. His serum beta human chorionic
growth hormone (β-HCG) level was 3.38 mIU/ml. A col-
onoscopy revealed a yellow tumor in the colon (Figure 2)
and endoscopic biopsy findings suggested a poorly dif-
ferentiated adenocarcinoma. After two days, a colectomy
was performed. The tumor located in the ascending
colon measured 4 cm × 5 cm and penetrated the serosa
and the mesocolic fat, with 12 adjacent enlarged lymph
nodes. The pathologic findings showed that the tumor
invaded the serosa of the intestinal wall and was com-
posed of syncytiotrophoblastic cells, cytotrophoblast-like
cells and intermediate trophoblastic cells. Necrosis and
hemorrhage were also noted in the mass. Immunohisto-
chemical staining was positive for HCG and negative for
cytokeratin 7, cytokeratin 20, villin, caudal type homeo-
box 2, α-fetoprotein and CD30 (Figure 3). Metastasis
was found in the liver and in eight of the excised lymph
nodes.
Systemic chemotherapy using bleomycin, etoposide
and platinum was performed. Chemotherapy engaging
etoposide phosphate 100 mg, cisplatin 30 mg, bleomycin
18 mg was initiated. The β-hCG level increased from
3.38 to 10,000 mIU/ml after the first course of chemo-
therapy, and CT showed another mass in the liver. After
three cycles of chemotherapy, his β-hCG level remained
high. Because of the progression of disease, the patient
and his family abandoned other alternative regimens of
chemotherapy.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Computed tomography. (A) Note the thickened wall of
the ascending colon (short arrow) and enlarged lymph nodes in the
mesentery (long arrow). (B) The hepatic lesion manifested
ring-shaped enhancement (arrow).
Figure 2 Endoscopic biopsy (A) Colonoscopy revealed a circular
yellow tumor in the ascending colon. (B) An endoscopic biopsy
revealed atypical epithelium (hematoxylin and eosin ×100).
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Choriocarcinoma most commonly arises in tropho-
blastic tissue following gestational events such as molar
pregnancy, normal or ectopic pregnancy, and abortion.
When the tumor occurs in men, the gonads are the
most common sites. Choriocarcinoma of extragenital
origin has been reported in the retroperitoneum [1],
mediastinum [2], and intracalvarium (especially in the
pineal gland [3]). When it occurs in the gastrointestinal
tract, the stomach is the most common site [4]. PCC
originating in the colon is extremely rare, with only 12
documented cases. In the literature, the mean age of
presentation with PCC of the colon is 51.4 years, and
the ratio of female to male is 1.6:1. Of the casesreported, 61.5% of patients presented with the tumor in
the proctosigmoid; the tumor was located in the ascend-
ing colon in three patients (Table 1).
The pathogenesis of primary extragenital choriocar-
cinoma is controversial. Several hypotheses have been
proposed, including that it develops from retained
primordial germ cells that migrated abnormally during
embryonic development [16]; metastasis from a latent
primary lesion in the genitalia [4]; and the retrodifferen-
tiation of pre-existing colonic carcinoma [8]. Among
them, the retrodifferentiation theory from pre-existing
colonic adenocarcinoma is well accepted. Given that
PCC of the colon associated with adenocarcinoma
accounts for 69.2% of reported cases, this theory
is considered to be logical. However, concurrent
Figure 3 Pathologic findings. (A) Pathologic findings of the
resected specimen revealed polynuclear giant cells. (B)
Immunohistochemical staining was positive for human chorionic
growth hormone.
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two of the previous cases [10,13]. An explanation for
choriocarcinoma unaccompanied by adenocarcinoma
could be that the tumor arises directly from malignant
change in the ectopic chorion or totipotent cells [13].
The preoperative diagnosis of PCC of the colon is poor.
In our case, the patient was assessed as having metastatic
colonic cancer. An endoscopic biopsy supported this pos-
sibility because of an insufficient specimen. However, on
postoperative biopsy, he was re-diagnosed with PCC of
the colon. The diagnosis of primary extragenital choriocar-
cinoma should firstly rule out any abnormal findings in
the uterus or genitalia. The presence of cytotrophoblast
and syncytiotrophoblast on biopsy, the presence of β-hCG
immunoreactive cells, and elevation of serum β-hCG level
confirm the diagnosis.
The majority of patients with gastric choriocarcinoma
are treated surgically. Umemori et al. found thatresection followed by adjuvant chemotherapy was the
best treatment of PCC of the lung [16]. For patients with
widespread metastasis, resection has proven ineffective
in prolonging survival. In patients without metastasis, a
combination of radical surgery and appropriate adjuvant
chemotherapy contributed to their long-term survival
[4]. The chemotherapy modality for primary extragenital
choriocarcinoma has not been established; most treat-
ment options are based on experience. The chemother-
apy regimens for choriocarcinoma and adenocarcinoma
are different. Chemotherapy for both the choriocarcin-
oma and the colonic adenocarcinoma is most logical
according to a study by Kubosawa et al. [4] – their pa-
tient showed the longest survival.
The correlation between the β-hCG level and the
effectiveness of treatment has not been detailed in most
previous reported cases. β-hCG did not decrease to
normal levels after surgery, implying that micrometa-
static disease existed [17]. The reduction of β-hCG in
the serum indicates response to treatment. After the re-
section of the primary lesion, the serum β-hCG level in
our case did not decrease to normal range. Abdominal
CT showed hepatic lesions when the serum β-hCG
increased. We suggest the serum β-hCG level could be
used as a marker when assessing the effectiveness of
treatment.Conclusions
The prognosis of PCC of the colon is poor. In our ana-
lysis of the literature, the median survival time was less
than 1 year. PCC of the colon is usually not identified
until the tumor has generalized metastasis. The great
majority of patients die from liver failure.Consent
Written informed consent was obtained from the patient
for publication of this manuscript.
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Table 1 Clinical characteristics of primary choriocarcinoma of colon
Case Sex and age (years) Location HCG
(mIU/ml)
Metastases on admission Associated with
adenocarcinoma?
Treatment Survival time
Park and Reid 1980 [5] F/49 S NS Liver lung Y Surgery 1 month
Nguyen 1982 [6] M/74 S 400 None Y Surgery 10 weeks
Ordonez and Luna 1984 [7] F/35 Cecum 1,612 Regional lymph nodes, liver Y Surgery 2 months
Kubosawa et al. 1984 [8] F/50 S 230,000 None Y Surgery 4 months
Metz et al. 1985 [9] F/42 S 154,000 Regional lymph nodes, liver, lung spleen Y None
Lind and Haghighi 1986 [10] M/42 A 610,000 Liver N Surgery 1 month
Tokisue et al. 1996 [11] F/29 R 49,000 Lung Y Surgery, chemotherapy 11 months
Kiran et al. 2001 [12] M/68 R 700,000 Regional lymph nodes, liver Y None
Le et al. 2003 [13] M/73 A 146,000 Liver, lung, brain N None 10 days
Verbeek et al. 2004 [14] F/54 R 6,831(P) Liver, lung Y Surgery, chemotherapy 8 months
Froylich et al. 2010 [15] F/57 Descending colon 13,000 (P) Lung N Surgery, chemotherapy 16 months
Harada et al. 2012 [4] F /58 S 2,420 None Y Surgery, chemotherapy More than 60 months
Present case 2012 M/38 A 3.38 Regional lymph nodes, liver N Surgery, chemotherapy More than 6 months
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